Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Blood (2023) 142 (Supplement 1): 6037.

https://doi.org/10.1182/blood-2023-180710

Published: 2023

Journal Articles

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Blood (2023) 142 (Supplement 1): 974.

https://doi.org/10.1182/blood-2023-180482

Published: 2023

Journal Articles

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Blood (2023) 142 (Supplement 1): 4223.

https://doi.org/10.1182/blood-2023-189800

Published: 2023

Journal Articles

Lentiviral-mediated Gene Therapy for Adults and Children with Severe Pyruvate Kinase Deficiency: Results from an Ongoing Global Phase 1 Study

Ami J. Shah, José Luis López Lorenzo, Julián Sevilla, Susana Navarro, Lucía Llanos, Begoña Pérez de Camino Gaisse, Sol Sanchez, Josune Zubicaray, Bert Glader, May Chien, Oscar Quintana Bustamante, Miriam Zeini, Grace Choi, Eileen Nicoletti, Gayatri R. Rao, Maria Grazia Roncarolo, Juan A. Bueren, Jonathan D. Schwartz, José C. Segovia

Blood (2022) 140 (Supplement 1): 4902–4903.

https://doi.org/10.1182/blood-2022-170948

Published: 2022

Journal Articles

Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients

Blood (2021) 138 (Supplement 1): 563.

https://doi.org/10.1182/blood-2021-148161

Published: 2021

Journal Articles

Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience from the Spanish Group of Hematopoietic Transplant (GETH-TC)

Blood (2021) 138 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2021-150992

Published: 2021

Journal Articles

Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients

Blood (2020) 136 (Supplement 1): 47.

https://doi.org/10.1182/blood-2020-137246

Published: 2020

Journal Articles

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups

Blood (2020) 136 (Supplement 1): 19.

https://doi.org/10.1182/blood-2020-134296

Published: 2020

Journal Articles

Correction of the Energetic Defects in Pyruvate Kinase Deficiency through Genome Editing in Hematopoietic Stem and Progenitor Cells

Sara Fañanas-Baquero, Oscar Quintana Bustamante, PhD, Daniel P. Dever, PhD, Omaira Alberquilla, Rebeca Sanchez-Dominguez, PhD, Joab Camarena, BS, Rolf Turk, José Luis López Lorenzo, MD, Paola Bianchi, BSc, PhD, Mark Behlke, MD PhD, Juan A Bueren, PhD, Matt Porteus, MD PhD, José C Segovia, PhD

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-139117

Published: 2020

Journal Articles

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Blood (2019) 134 (Supplement_1): 3891.

https://doi.org/10.1182/blood-2019-127187

Published: 2019

Journal Articles

Comparation of Digital PCR and Quantitative Pcr for Molecular Monitorization of Chronic Myeloid Leukemia Patients

Juan Manuel Alonso Dominguez, MD PhD MSc, Rodrigo Iñiguez Garcia, MD, Susana Olmedillas, PhD, Rocio N Salgado, PhD, Tamara Castaño, MD, Carlos Blas, MD, Diego Velasco Rodrgiguez, MD PhD, Gala Vega, MD, Jose Luis Lopez Lorenzo, MD, Pilar Giraldo, PhD, Joaquin Martinez Lopez, MD PhD, Pilar Llamas, MDPhD, Mireia Atance, Arantxa Garcías Raso

Blood (2017) 130 (Supplement 1): 2891.

https://doi.org/10.1182/blood.V130.Suppl_1.2891.2891

Published: 2017

Journal Articles

Characterization of Ex-Vivo PTCH1 Expression Under Tyrosine Kinase Inhibitors Treatment and Determination of Downstream Effectors Oh Hedgehog Pathway in CML

Juan Manuel Alonso Dominguez, MD PhD MSc, Alicia Arenas, PhD, Pilar Llamas, MDPhD, Diego Velasco, Aránzazu García-Raso, PhD, Jose Luis Lopez Lorenzo, MD, Mireia Atance, Rocio N Salgado, PhD, Joaquin Martinez Lopez, MD PhD

Blood (2017) 130 (Supplement 1): 5245.

https://doi.org/10.1182/blood.V130.Suppl_1.5245.5245

Published: 2017

Journal Articles

Preliminary Results of the Flugaza Trial: A Phase III Randomized, Open Label Study Comparing Azacytidine Versus Fludarabine and Cytarabine (FLUGA Scheme) in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Blood (2016) 128 (22): 4036.

https://doi.org/10.1182/blood.V128.22.4036.4036

Published: 2016

Journal Articles

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Valentín García-Gutiérrez, Dragana Milojkovic, María Luisa Martín Mateos, Simone Claudiani, Concepcion Boque, PhD, Luis Felipe Casado, Gloria González, Antonio Jiménez, Alejandra Martinez Trillos, Isabel Mata Vázquez, Ángel Ramírez Payer, Alberto Álvarez Larran, Elena Amutio Díez, Abelardo Bárez García, MD, Guiomar Bautista Carrascosa, Sabela Bobillo Varela, Beatriz Cuevas Ruiz, Mª Ángeles Fernández Fernández, María del Carmen García Garay, Pilar Giraldo, MD PhD, Jose María Guinea de Castro, Natalia De Las Heras Rodríguez, MD, Nuria Hernanz Soler, Ana Iglesias Pérez, José Luis López Lorenzo, Josep Maria Martí Tutusaus, MD PhD, Rolando Omar Vallansot, Fernando Ortega Rivas, Jose Manuel Puerta, Maria Jose Ramírez Sánchez, Esperanza Romero Picos, Mario Andrés Romo Collada, Ana Rosell Mas, Silvana Saavedra Gerosa, Ana Sebrango Sadia, José Tallón Pérez, Sandra Valencia, Juan Luis Steegmann, MD

Blood (2015) 126 (23): 2786.

https://doi.org/10.1182/blood.V126.23.2786.2786

Published: 2015

Journal Articles

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

Blood (2014) 124 (21): 5523.

https://doi.org/10.1182/blood.V124.21.5523.5523

Published: 2014

Journal Articles

Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predicitive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase( CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial

Blood (2013) 122 (21): 5190.

https://doi.org/10.1182/blood.V122.21.5190.5190

Published: 2013

Journal Articles

Clofarabine in Acute Myeloid Leukemia. the Spanish Experience

Blood (2011) 118 (21): 4279.

https://doi.org/10.1182/blood.V118.21.4279.4279

Published: 2011

Journal Articles

Clinical Experience of Bendamustine Treatment for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Spanish Registry.

Blood (2009) 114 (22): 3698.

https://doi.org/10.1182/blood.V114.22.3698.3698

Published: 2009

NARROW

Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

The FLT3-like Gene Expression Signature Predicts Response to Quizartinib in Wild-Type FLT3 Acute Myeloid Leukemia: An Analysis of the Pethema Quiwi Trial

Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry

Lentiviral-mediated Gene Therapy for Adults and Children with Severe Pyruvate Kinase Deficiency: Results from an Ongoing Global Phase 1 Study

Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients

Management of Donor-Specific Antibodies in Haploidentical Transplant: Multicenter Experience from the Spanish Group of Hematopoietic Transplant (GETH-TC)

Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients

Frequency, Clinical Characteristics and Outcome of Adult Patients with Acute Lymphoblastic Leukemia (ALL) and COVID-19 in Spain: Results of a Survey from Pethema and Geth Groups

Correction of the Energetic Defects in Pyruvate Kinase Deficiency through Genome Editing in Hematopoietic Stem and Progenitor Cells

Mutational Profiling Predicts Clinical Outcomes to Azacytidine and Low Dose Cytarabine Plus Fludarabine (FLUGA) in Elderly Acute Myeloid Leukemia Patients Enrolled in the Pethema Phase III Flugaza Trial

Comparation of Digital PCR and Quantitative Pcr for Molecular Monitorization of Chronic Myeloid Leukemia Patients

Characterization of Ex-Vivo PTCH1 Expression Under Tyrosine Kinase Inhibitors Treatment and Determination of Downstream Effectors Oh Hedgehog Pathway in CML

Preliminary Results of the Flugaza Trial: A Phase III Randomized, Open Label Study Comparing Azacytidine Versus Fludarabine and Cytarabine (FLUGA Scheme) in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients

Bosutinib Apears to be Safe, with Low Cross Intolerance, in Patients Treated in 4th Line. Results of the Spanish Compassionate Use Program

Very Early Molecular Responses During The First Two Months Of Therapy Are Highly Predicitive Of Deep Molecular Responses In Newly-Diagnosed Chronic Myeloid Leukemia In Chronic Phase( CML-CP) Patients Treated Upfront With Nilotinib. The Spanish Substudy Of The ENEST1st Trial

Clofarabine in Acute Myeloid Leukemia. the Spanish Experience

Clinical Experience of Bendamustine Treatment for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Spanish Registry.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only